Glucose excursions in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial
Phase 4
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024817
- Lead Sponsor
- Kitano Hospital
- Brief Summary
The mean glucose levels in the mitiglinide/voglibose and glimepiride groups were almost equal. the mitiglinide/voglibose group showed a significantly lower SD of glucose, MAGE, M-value, CONGA-1 value, and AUC >10 mmol/L than the glimepiride group. Hypoglycemia was not observed with mitiglinide/voglibose, whereas it was observed 0.35 times per day with glimepiride.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
patients with insulin dependent diabetes; known allergies to mitiglinide, voglibose, or glimepiride; hepatic dysfunction; renal dysfunction; use of corticosteroids; existing pregnancy; alcoholism; a history of severe hypoglycemic episodes; a history of diabetic ketoacidosis; diabetic retinopathy with a high risk of hemorrhage
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Glycemic excursions and the frequency of hypoglycemic evaluated using CGM on the last day of both periods
- Secondary Outcome Measures
Name Time Method Metabolic profile changes during MTT